Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Abstract: Approximate computing, frequently used in error tolerant applications, aims to achieve higher circuit performances by allowing the possibility of inaccurate ...

The new major version with a new JIT compiler, a revised parallelization API, and a maturing type system paves the way for ...